HDMA names six new directors; ABC’s Neu appointed vice chair
ARLINGTON, Va. — The Healthcare Distribution Management Association on Tuesday named six new members to its board of directors — Maria Burns, Burlington Drug Co. VP and corporate secretart; Gregory Drew, Value Drug Co. president; Terrance Haas, Harvard Drug Group CEO; David Neu, AmerisourceBergen president; Dale Smith, H. D. Smith chairman and CEO; and Albert Thomas, senior director and general manager of VaxServe, a Sanofi Pasteur company.
Additionally, Neu was elected vice chairman of the HDMA board. David Moody, Jr., CEO Mutual Wholesale Drug Co., will continue to serve as chairman.
“I want to welcome our six new directors and thank our outgoing members for their commitment to our association and the healthcare distribution industry,” HDMA president and CEO John Gray said. “I look forward to working closely with the HDMA board of directors as we address the critical issues affecting our industry and advocate for safe and efficient supply chain solutions.”
ADHD can be diagnosed in children from age 4, physician group says
BOSTON — Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.
In a new report, the children’s physician group said emerging evidence made it possible to diagnose and manage ADHD from the ages 4 to 18 years; previous guidelines, released in 2000 and 2001, included children ages 6 to 12 years. The AAP recommends behavioral interventions in children ages 4 and 5 years, while methylphenidate "may be considered" for preschool children with moderate to severe symptoms who do not experience significant improvement with behavior therapy. A mix of drug and behavior therapy is recommended for elementary school children and adolescents.
"Treating children at a young age is important because when we can identify them earlier and provide appropriate treatment we can increase their chances of succeeding in school," report lead author Mark Wolraich said. "Because of greater awareness about ADHD and better ways of diagnosing and treating this disorder, more children are being helped."
The AAP released the report, titled "ADHD: Clinical Practice Guidelines for the Diagnosis, Evaluation and Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder," at its National Conference & Exhibition in Boston Sunday. It will also be published in the November 2011 issue of the journal Pediatrics.
Vivus resubmits application for Qnexa
MOUNTAIN VIEW, Calif. — Vivus has reapplied to the Food and Drug Administration for approval of a drug to treat obesity, the company said Monday.
Vivus said it sent in its regulatory approval application for Qnexa (phentermine and topiramate), a drug designed to treat obese and overweight patients by inducing and maintaining weight loss.
The company originally sought approval for the drug in October 2010, though the FDA declined to approve it.